Eisai Pays up to $2B for ADC Bearing Its Halaven as Payload

Eisai Pays up to $2B for ADC Bearing Its Halaven as Payload

Source: 
BioSpace
snippet: 

In the latest deal in a resurgent space, Eisai announced Monday it would pay Bliss Biopharmaceutical up to $2 billion in a clinical trial collaboration for an antibody-drug conjugate carrying its chemotherapy drug Halaven (eribulin).